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SUMMARY  Th ese are evidence based guidelines for the management of patients with carotid 
stenosis, developed and endorsed by Croatian Society of Neurovascular Disorders, Croatian Society 
of Neurology, Croatian Society of Ultrasound in Medicine and Biology, Croatian Society for Ra-
diology, Croatian Society of Vascular Surgery and Croatian Society of Neurosurgery. Th ey consist 
of recommendations for noninvasive screening of patients with carotid stenosis, best medical treat-
ment and interventions such as carotid endarterectomy and stent placement based on international 
randomized clinical trials.   
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Introduction
Stenosis of internal carotid artery (ICA) causes 
stroke, as demonstrated by randomized trials, which 
have shown that removing the extracranial ICA 
stenosis by means of carotid endarterectomy (CEA) 
signifi cantly reduces the risk of subsequent ischemic 
stroke in ipsilateral carotid territory1,2. Observational 
studies suggest that about one-quarter of all fi rst-
ever ischemic strokes and transient ischemic attacks 
(TIAs) are caused by atherothromboembolism origi-
nating from the extracranial ICA3. 
Large artery atherosclerosis may cause almost any 
clinical stroke syndrome, with the clinical spectrum 
ranging from asymptomatic arterial disease, TIA af-
fecting the eye or the brain, and ischemic stroke of 
any severity in the anterior and posterior circula-
tion. Carotid stenosis causes symptoms through two 
mechanisms: artery-to-artery embolism and low fl ow 
states. Artery-to artery embolism is considered the 
most common mechanism, through emboli consist-
ing of platelet aggregates, from thrombus formed on 
atherosclerotic plaques, or from atherosclerotic debris 
or cholesterol crystals. Th e triad of vessel wall lesion, 
blood cells and plasma factors all contribute to throm-
bosis at any site. Severe stenosis alters blood fl ow char-
acteristics, and turbulence replaces laminar fl ow when 
the degree of stenosis exceeds about 70%. Platelets are 
activated when exposed to abnormal or denuded en-
dothelium in the region of an atheromatous plaque. 
Plaque hemorrhage may contribute to thrombus for-
mation. In cases of high-grade stenosis, it can be dif-
fi cult to discriminate between the two mechanisms 
with absolute certainty. Transcranial Doppler (TCD), 
an ultrasound examination of the intracranial vessels, 
can provide direct evidence of the hemodynamic sig-
nifi cance of the carotid lesion, and also off ers the pos-
sibility to detect the embolic signals4. Brain comput-
erized tomography (CT) provides information on the 
stroke type4. Lesions of low fl ow states are typically 
localized in distal brain regions, particularly in arte-
rial border zones, and thus referred to as ‘watershed 
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infarction’. Artery-to-artery embolism results in ter-
ritorial infarction. 
Th e risk of stroke ipsilateral to ICA stenosis in-
creases with the degree of symptomatic carotid steno-
sis until the artery distal to the stenosis begins to 
collapse1,2 (stenosis increase per 10% hazard rate (HR) 
1.18; 95%CI 1.10-1.25)5. Paradoxically, these patients 
with ICA narrowed or collapsed due to markedly re-
duced post-stenotic blood fl ow (pseudo-occlusion, 
near-occlusion) have a low risk of stroke on best med-
Table 1. Classifi cation of evidence for diagnostic and therapeutic measures
Evidence classifi cation scheme for a diagnostic measure 
Evidence classifi cation scheme for a therapeutic 
intervention 
Class I 
A prospective study in a broad spectrum 
of persons with the suspected condition, 
using a 'gold standard' for case defi ni-
tion, where the test is applied in a blinded 
evaluation, and enabling the assessment of 
appropriate tests of diagnostic accuracy 
An adequately powered, prospective, randomized, 
controlled clinical trial with masked outcome assess-
ment in a representative population or an adequately 
powered systematic review of prospective randomized 
controlled clinical trials with masked outcome assess-
ment in representative populations. Th e following are 
required: 
(a) randomization concealment 
(b) primary outcome(s) is/are clearly defi ned 
(c) exclusion/inclusion criteria are clearly defi ned 
(d) adequate accounting for dropouts and crossovers
      with numbers suffi  ciently low to have a minimal
      potential for bias; and 
(e) relevant baseline characteristics are presented and 
substantially equivalent among treatment groups 
or there is appropriate statistical adjustment for 
diff erences 
Class II 
A prospective study of a narrow spectrum 
of persons with the suspected condition, 
or a well-designed retrospective study 
of a broad spectrum of persons with an 
established condition (by 'gold standard') 
compared to a broad spectrum of controls, 
where test is applied in a blinded evalua-
tion, and enabling the assessment of ap-
propriate tests of diagnostic accuracy 
Prospective matched-group cohort study in a repre-
sentative population with masked outcome assess-
ment that meets a-e above or a randomized, con-
trolled trial in a representative population that lacks 
one criterion a-e 
Class III 
Evidence provided by a retrospective study 
where either persons with the established 
condition or controls are of a narrow 
spectrum, and where test is applied in a 
blinded evaluation 
All other controlled trials (including well-defi ned 
natural history controls or patients serving as own 
controls) in a representative population, where out-
come assessment is independent of patient treatment 
Class IV 
Evidence from uncontrolled studies, case 
series, case reports, or expert opinion 
Evidence from uncontrolled studies, case series, case 
reports, or expert opinion 
ical treatment alone6,7 (HR 0.49; 95%CI 0.19-1.24). 
Th e risk of stroke ipsilateral to ICA stenosis is greater 
in patients with recent neurologic symptoms of isch-
emia in the ipsilateral carotid territory8,9, with the 
presenting event as follows: major stroke (HR 2.54; 
95%CI 1.48-4.35), multiple TIAs (HR 2,05; 95%CI 
0.16-3.60), minor stroke (HR 1.82; 95%CI 0.99-3.34), 
single TIA (HR 1.41; 95%CI 0.75-2.66), and ocular 
event (HR 1.0)5. Th e high early risk of recurrence is 
the consequence of the instability of atherosclerotic 
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plaque, and the rapid decline in the risk over the sub-
sequent year possibly refl ects the healing of the un-
stable atheromatous plaque or an increase in collateral 
blood fl ow to the symptomatic hemisphere7. Plaque 
instability is characterized by a thin fi brous cap, large 
lipid core, reduced smooth muscle content, and high 
macrophage density; complicating thrombosis occurs 
mainly when the thrombogenic center of the plaque 
is exposed to fl owing blood. Other factors increasing 
the risk of stroke in the presence of carotid stenosis 
are the increasing age, irregular and ulcerated plaque 
morphology (HR 2.03; 95%CI 1.31-3.14)5, absence 
of collateral fl ow, impaired cerebral reactivity, TCD 
fi ndings of microembolic signals, hypertension and 
coronary heart disease. 
Th e purpose of revascularization of a symptomatic 
extracranial ICA stenosis is reduction in the risk of 
recurrent ipsilateral carotid territory ischemic stroke 
by removing the source of carotid thromboembolism.
After evaluation of the results of large internation-
al randomized controlled trials (RCTs), the Croatian 
Society of Neurovascular Disorders, Croatian Soci-
ety of Neurology, Croatian Society of Ultrasound in 
Medicine and Biology, Croatian Society of Radiology, 
Croatian Society of Vascular Surgery and Croatian 
Society of Neurosurgery have reached a consensus and 
present herewith the guidelines based on the levels of 
recommendations for the treatment of patients with 
carotid stenosis. Th e classes of evidence and levels of 
recommendations used in these guidelines are defi ned 
according to the criteria of the European Federa-
tion of Neurological Societies (EFNS) (Tables 1 and 
2)10. Recommendations are in accordance with EUSI 
(European Stroke Initiative) guidelines on ischemic 
stroke management, with the European Neurological 
Society, European Federation of Neurological Societ-
ies and European Stroke Council representing Euro-
pean Stroke Conference, as well as with other pub-
lished North American stroke guidelines, American 
Heart Association (AHA) guidelines on intracranial 
neurointerventional procedures, and European Soci-
ety of Vascular Surgery guidelines.
Transient Ischemic Attack as a Risk Factor for Stroke
Transient ischemic attack is a brief episode of 
neurologic dysfunction resulting from focal cerebral 
ischemia not associated with permanent cerebral in-
farction11. Among patients presenting with stroke, the 
prevalence of prior TIA has been reported to range 
from 7% to 40%. Th e percentage varies, depending 
on factors such as how TIA is defi ned, which stroke 
subtypes are evaluated, and whether the study is a 
population-based or hospital-based series12,13. In the 
population-based Northern Manhattan Stroke Study, 
the prevalence of TIAs among those that presented 
with fi rst ischemic stroke was 8.7%14, with the major-
ity of TIA occurring within 30 days of the patient’s 
fi rst ischemic stroke. An even higher rate has been re-
ported in patients with prior stroke15,16 and as great as 
50% among those with atherothrombotic stroke. Th e 
timing of a TIA before stroke was highly consistent, 
with 17% occurring on the day of stroke, 9% on the 
previous day, and another 43% at the same point dur-
ing the 7 days before the stroke17-20. It has long been 
Table 2. Defi nitions of the levels of recommendation
Level A 
Established as useful/predictive or not useful/predictive for a diagnostic measure or established 
as eff ective, ineff ective or harmful for a therapeutic intervention; requires at least one convincing 
Class I study or at least two consistent, convincing Class II studies. 
Level B 
Established as probably useful/predictive or not useful/predictive for a diagnostic measure or 
established as probably eff ective, ineff ective or harmful for a therapeutic intervention; requires at 
least one convincing Class II study or overwhelming Class III evidence. 
Level C 
Established as possibly useful/predictive or not useful/predictive for a diagnostic measure or 
established as possibly eff ective, ineff ective or harmful for a therapeutic intervention; requires at 




Recommended best practice based on the experience of the guideline development group. Usu-
ally based on Class IV evidence indicating large clinical uncertainty, such GCP points can be 
useful for health workers 
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recognized that TIA can portend stroke21, and studies 
have shown elevated long-term stroke risk22-24. Stud-
ies have also shown that the short-term stroke risk is 
particularly high, exceeding 10% in 90 days12,20,25-28. 
Th e risk is particularly high in the fi rst few days after 
TIA, and several score systems based on clinical char-
acteristics, such as California score and ABCD score, 
help distinguish patients at a lower risk from those at 
an increased risk29. Th e newer ABCD2 score has been 
derived to provide a more robust prediction standard 
and incorporates elements from both prior scores29. In 
addition, patients with severe extra- or intracranial 
stenosis carry a particularly high risk of recurrence30. 
Imaging of the brain and supplying vessels is 
crucial in the assessment of patients with stroke and 
TIA. Brain imaging distinguishes ischemic stroke 
from intracranial hemorrhage and stroke mimics, and 
identifi es the type and often also the cause of stroke; it 
may also help diff erentiate irreversibly damaged tissue 
from areas that may recover, thus guiding emergency 
and subsequent treatment, and may help predict the 
outcome.
Vascular evaluation for assessment may identify 
the site and cause of arterial obstruction, and identifi es 
patients at a high risk of stroke or stroke recurrence31-
35. Observational studies have shown that urgent 
evaluation at a TIA clinic and immediate initiation 
of treatment reduces stroke risk after TIA36,37. It has 
been shown that early management of TIA patients at 
a stroke unit leads to specifi c treatments in a signifi -
cant proportion of cases38.
Carotid stenosis of >50% of ICA is found in 8%-
31% of patients with TIA and minor stroke39,40. Ca-
rotid ultrasound provides reliable assessment of the 
carotid bifurcation, with reported sensitivity of 75% 
and specifi city of 98%41, or sensitivity of 88% and 
specifi city of 76%42. Carotid duplex examination has 
prognostic signifi cance. In TIA patients, carotid du-
plex and TCD performed within 24 hours of symp-
toms revealed a 3-fold risk of stroke within 90 days of 
follow up in patients with moderate to severe extra- or 
intracranial carotid stenosis43. 
TCD provides information on intracranial steno-
sis32, with a positive predictive value (PPV) of 36% 
and negative predictive value (NPV) of 86%44. Th e 
high NPV and lower PPV refl ect a low prevalence of 
intracranial stenosis45, and the prevalence of intracra-
nial disease is much higher in non-white population. 
TCD can detect microembolic signals (MESs) 
seen with extracranial or cardiac sources of embolism. 
High numbers of MESs are a marker of risk in pa-
tients with TIA of carotid origin, spurring research 
into optimal strategies for medical therapy and tim-
ing of endarterectomy in those with an extracranial 
carotid source45. In a cohort of patients unselected 
for stroke mechanism, MESs were more common in 
patients with large artery occlusive disease and were 
more prevalent in patients treated with anticoagula-
tion than in those treated with antiplatelet agents46. 
Th e CARESS trial45 enrolled recently symptomatic 
carotid disease and MESs and found fewer patients 
with MESs, fewer MESs per hour and fewer stroke 
in patients treated with clopidogrel and aspirin than 
in patients treated with aspirin alone in the fi rst week 
of presentation.
Recommendations for Diagnostic Management of 
Patients with TIA or Stroke
It is recommended that all stroke patients should 
be treated at a stroke unit (Class I, Level A).
It is recommended that patients with suspected 
TIA are investigated and treated as emergencies at 
a TIA clinic with specialized assessment (Class III, 
Level B) or admitted to a stroke unit. Th e overall sec-
ondary prevention strategies for TIA patients do not 
diff er from those for patients with completed stroke.
Patients with TIA, minor stroke, early sponta-
neous recovery or defi nitive stroke should undergo 
immediate diagnostic work-up within 24 hours of 
symptom onset,  including urgent vascular imaging 
(ultrasound, CT angiography, or MR angiography) 
(Class I, Level A)
Noninvasive imaging of the cervicocephalic vessels 
should be performed routinely as part of the evaluation 
of patients with TIA or stroke (Class I, Level A).
Asymptomatic Carotid Disease
Several years ago, it was estimated47 that approxi-
mately 2 million people living in Europe and North 
America have asymptomatic extracranial carotid ar-
tery stenosis that could be considered for treatment. 
Carotid endarterectomy and, recently, carotid artery 
stenting have been used for the treatment of carotid ar-
tery stenosis. It has been shown that the risk of stroke 
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increases with the degree of stenosis (less than 1% per 
year for <80% stenosis, increasing to 4.8% per year for 
>90% stenosis). Th erefore, the benefi t of screening for 
asymptomatic severe carotid artery stenosis depends 
on the prevalence of disease, the sensitivity and speci-
fi city of the screening tool, and the complication rates 
of angiography and surgery. In addition, the costs of 
diagnosis and treatment must be considered.
Most of the evidence in the literature regarding 
patient selection are based on studies using Doppler 
ultrasound. Th erefore, a Multidisciplinary Practice 
Guidelines Committee of the American Society of 
Neuroimaging, cosponsored by the Society of Vas-
cular and Interventional Neurology was formed to 
identify the group of predominantly asymptomatic 
patients who would benefi t from screening for ca-
rotid artery stenosis48. Th e Committee decided that 
the value of screening in any subset of population was 
dependent on the expected prevalence and anticipated 
benefi t from intervention (for example, the overall 
high incidence was evaluated against comorbidities 
and life expectancy in that subset of population). Th e 
grading of the strength of the scientifi c evidence used 
to create the recommendations was derived from the 
disease prevalence in the population subset and docu-
mented benefi t of the treatment (Table 3). Th e antici-
pated benefi t of treatment in asymptomatic patients 
with carotid stenosis was derived from three random-
ized clinical trials. Two trials compared carotid en-
darterectomy with best medical treatment in patients 
with asymptomatic carotid stenosis49,50, and the third 
trial compared carotid stenting with carotid endart-
erectomy51. 
In the Asymptomatic Carotid Atherosclerosis 
Study (ACAS)49, patients with asymptomatic carotid 
artery stenosis of 60% or greater, defi ned by angiogra-
phy or Doppler evaluation using a local laboratory cut-
off  point, were randomized to CEA or best medical 
management. After a median follow up of 2.7 years, 
the aggregate risk over 5 years for ipsilateral stroke 
and any perioperative stroke or death was estimated 
to be 5.1% for surgical patients and 11.0% for patients 
treated medically (aggregate risk reduction by 53%; 
absolute risk reduction by approximately 1% per year). 
Th e benefi t was dependent on carotid endarterecto-
my being performed with less than 3% perioperative 
morbidity and mortality. Th e Asymptomatic Carotid 
Surgery Trial (ACST)50 randomized asymptomatic 
patients with signifi cant carotid stenosis according to 
Doppler criteria to immediate CEA or indefi nite de-
ferral of any CEA. Th e mean follow up was 3.4 years. 
Th e cumulative 5-year risks were 6% versus 12% for 
all strokes, 4% versus 6% for fatal or disabling strokes, 
and 2% versus 4% for only fatal strokes. Subgroup-
specifi c analyses found no signifi cant heterogeneity in 
the perioperative risk or long-term postoperative ben-
efi ts. A meta-analysis of three trials52 has found that 
despite a 3% perioperative stroke or death rate, carotid 
endarterectomy for asymptomatic carotid stenosis re-
duces the risk of ipsilateral stroke and any stroke by 
approximately 30% over 3 years. For the outcome of 
any stroke or death, there was a nonsignifi cant trend 
toward fewer events in the CEA group. In subgroup 
analysis, CEA appeared more benefi cial in men than 
in women and more benefi cial in younger patients than 
in older patients, although data on age eff ect were in-
conclusive. Th ere was no statistically signifi cant diff er-
ence between the treatment eff ect estimates in patients 
with diff erent grades of signifi cant stenosis, but the 
data were insuffi  cient. Th e Stenting and Angioplasty 
with Protection in Patients at High Risk for Endar-
terectomy (SAPPHIRE)51 compared carotid stenting 
(CAS) (with the use of an emboli-protection device) 
to CEA in patients considered to be at a high surgical 
risk for CEA. Patients were eligible if they had either 
symptomatic stenosis of 50% or greater or asymptomat-
ic stenosis of 80% or greater. Th e primary end point of 
the trial was the cumulative incidence of death, stroke, 
or myocardial infarction within 30 days of the proce-
dure, or death or ipsilateral stroke between 31 days and 
1 year. Th e primary end point occurred in 20 (12%) pa-
tients randomly assigned to undergo CAS and in 32 
(20%) patients randomly assigned to undergo CEA. 
For patients with asymptomatic carotid artery stenosis, 
the cumulative incidence of the primary end point at 1 
year was lower among those treated with CAS (10%) 
than among those that underwent CEA (22%). In the 
periprocedural period, the cumulative incidence of 
death, myocardial infarction, or stroke among patients 
with asymptomatic carotid artery stenosis was 5% in 
those that received a stent, as compared to 10% in those 
that underwent CEA.
Th e prevalence of asymptomatic ICA stenosis for 
determination of the screening eff ectiveness was grad-
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ed as high (20% or greater), intermediate (between 5% 
and 20%) and low (less than 5%). While screening in 
the high prevalence group reduces the risk of stroke in 
a cost-eff ective manner, in the intermediate group it 
was only recorded in some studies. In this group, the 
benefi t is marginal and is lost if perioperative com-
plications exceed 5%. In the low prevalence group, 
screening has not been shown to reduce the risk of 
stroke, and in some studies it could even be harmful.
According to the expected benefi t of CEA in ACAS and 
ACST, the following recommendations for screening of 
patients with asymptomatic carotid stenosis have been 
proposed48:
In general population, screening of the selected 
subpopulation aged 65 years or older with at least 
three cardiovascular risk factors (hypertension, coro-
nary artery disease, current cigarette smoking or hy-
perlipidemia) is recommended (grade A).
In patients undergoing coronary artery bypass 
grafting, screening of all patients can be considered 
(grade D), and of selected patients is strongly recom-
mended: age 65 years or greater with either a history 
of stroke or TIA, left main coronary stenosis, periph-
eral vascular disease, history of cigarette smoking, ca-
rotid bruit, previous carotid surgery or diabetes mel-
litus (grade B).
In patients with peripheral vascular disease, 
screening of all patients with symptomatic peripheral 
vascular disease is strongly recommended (grade A), 
but existing data do not support routine screening of 
asymptomatic peripheral vascular diseases (grade E). 
Screening is recommended for all patients that 
have received unilateral or bilateral irradiation to the 
neck for head or neck cancer 10 years after treatment 
(grade B), due to improving survival observed in these 
patients and availability of carotid stent placement. 
However, no clear relationship has been demonstrated 
between the dose and duration of radiation treatment 
to allow for incorporation of radiation dose informa-
tion into the paradigm for selection of patients for 
screening.
In patients that have undergone CEA is recom-
mended in those that develop ipsilateral ischemic 
stroke, retinal ischemic events or TIA, screening 
(grade B)
Screening of patients that have undergone CAS is 
recommended in those that develop ipsilateral isch-
emic stroke, retinal ischemic events, or TIA after its 
placement (grade C).
Screening for carotid artery stenosis is recom-
mended for all patients with transient or permanent 
retinal ischemic event, particularly in the absence of 
migraine or cardiac sources of emboli (grade A), since 
most of the evidence regarding the benefi cial eff ect of 
CEA derive from patients with transient retinal isch-
emia. 
Considering patients that have undergone CEA, 
routine screening of all patients cannot be recom-
mended based on the low prevalence of restenosis and 
lack of correlation between restenosis and late stroke 
(grade E). Reoperation or stenting (CEA, CAS) has 
been considered for patients with symptomatic rest-
enosis or selected high-grade asymptomatic restenosis, 
although there is the lack of evidence demonstrating 
the benefi t from intervening in patients with restenosis 
using these indications. Th e optimal interval between 
CEA/CAS and ultrasound remains unclear, but the 
Table 3. Criteria for grading the strength of scientifi c evidence used in the recommendations
A Prevalence of disease is high and detection and treatment is of documented benefi t (confi rmed by randomized tri-
als)
B Prevalence of disease is high but detection and treatment is of possible benefi t (confi rmed by comparison with 
nonrandomized concurrent or historic controls)
C Prevalence of disease is intermediate but detection and treatment is of documented benefi t (confi rmed by random-
ized trials)
D Prevalence of disease is intermediate and detection and treatment is of possible benefi t (confi rmed by comparison 
with nonrandomized concurrent or historic controls)
E Prevalence of disease may be high or low but detection and treatment is documented to have no benefi t, or preva-
lence of disease is low
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highest yield appears to be in studies performed be-
tween 3 and 18 months. 
Further studies need to validate the practice of per-
forming ultrasound screening at 1 month, 6 months 
and 12 months following carotid stent placement. 
Studies are required to develop Doppler ultrasound 
criteria with higher specifi city. 
No defi nite comments have been made regarding 
routine screening of all patients that have undergone 
CAS. Th ere is considerable variation in the rates of 
restenosis following CAS. Patients with restenosis 
following endovascular treatment were more likely to 
be symptomatic compared with restenosis following 
carotid endarterectomy47. Repeat endovascular treat-
ment has been considered for patients with symptom-
atic restenosis or selected high-grade asymptomatic 
restenosis, although there is the lack of evidence dem-
onstrating benefi t from intervening in patients with 
restenosis using these indications. 
Screening of all patients or asymptomatic patients 
with abdominal aortic aneurysm is not recommended 
(grade E), but the existing data support screening of 
patients with abdominal aortic aneurysm and history 
of TIA, ischemic stroke or retinal ischemic events 
(grade B).
Screening of all patients with renal artery stenosis 
is not recommended (grade E), but the Committee 
acknowledges that there are limited data available and 
encourages further studies to evaluate the value of 
carotid artery disease screening among patients with 
atherosclerotic renal artery stenosis of 60% or greater.
In patients that have undergone CEA screening 
should be considered for those with contralateral ca-
rotid artery stenosis >50% (grade A). Screening may be 
considered for patients with contralateral disease <50% 
(grade C). Because progression of stenosis in the con-
tralateral artery has a higher likelihood of becoming 
symptomatic, annual screening may be considered.
Medical Treatment of Patients with Carotid Stenosis
In primary as well as in secondary prevention in 
patients with carotid stenosis, treatment of risk fac-
tors such as hypertension, diabetes mellitus, lipid or 
homocysteine metabolic disorders, and modifi cation 
of lifestyle are of utmost importance to reduce both 
early and long-term risks of vascular events, dementia 
and death31,53. 
Aspirin, a combination of aspirin and extended re-
lease dipyridamole, clopidogrel, ticlopidine and trifl usal 
have been shown to be eff ective as antiplatelet agents in 
long-term secondary prevention of ischemic stroke54,55, 
but only aspirin, aspirin/extended dipyridamole and 
clopidogrel are widely used in clinical practice. 
To date, only aspirin has been shown to be safe 
and eff ective in the acute post-ischemic phase (fi rst 48 
hours) and should be started immediately in patients 
with TIA/ischemic stroke after exclusion of brain 
hemorrhage by brain imaging. Aspirin is eff ective ir-
respective of dose (30-1,300 mg/day), but doses >150 
mg/day are associated with more side eff ects56. In the 
Antithrombotic Trialists’ Collaboration, a meta-anal-
ysis of >60 aspirin trials, the best risk reduction was 
found in trials using a 75 to 150 mg dose of aspirin57-
59. Gastrointestinal side eff ects and bleeding rates in-
crease with higher doses of aspirin. In patients with 
a history of aspirin-induced ulcer bleeding, aspirin in 
combination with a proton pump inhibitor was supe-
rior to clopidogrel alone in the prevention of recurrent 
ulcer bleeding60.
Clopidogrel (75 mg/day) was slightly more eff ec-
tive than aspirin monotherapy (325 mg/day) in pre-
venting vascular events (ischemic stroke, myocardial 
infarction, or vascular death), resulting in a relative 
risk reduction (RRR) by 8.7% (95%CI 0.3-16.5)61. 
Th e highest benefi t of clopidogrel was seen in patients 
with concomitant peripheral artery disease. 
Th e combination of aspirin (30-300 mg/day) and 
extended release dipyridamole (200 mg twice a day) 
was shown to be more eff ective compared with aspirin 
alone in two studies62,63. Combination therapy reduced 
vascular events (ischemic stroke, myocardial infarction 
or vascular death) by 18% (95%CI 9%-26%). Reduced 
development of headache on combination therapy can 
be achieved with slower titration.
Th e PRoFESS trial64 was a head-to-head compari-
son of clopidogrel and the combination of aspirin/ex-
tended release dipyridamole. Th ere was no diff erence 
in effi  cacy across all endpoints and patient subgroups. 
Th e combination of aspirin/extended release dipyri-
damole resulted in more intracranial bleeding and a 
higher dropout rate due to headache compared with 
clopidogrel (5.9% vs. 0.9%).
In the MATCH trial (secondary prevention in 
high-risk patients with TIA or ischemic stroke)65 and 
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CHARISMA (Combined Primary and Secondary 
Prevention Study) trial66, comparison of clopidogrel 
or aspirin monotherapy with their combination failed 
to show superiority of combination therapy and re-
sulted in an increased bleeding rate. Th e Clopidogrel 
and Aspirin for Reduction of Emboli in Symptomatic 
Carotid Stenosis (CARESS) trial showed the combi-
nation therapy with clopidogrel and aspirin to be more 
eff ective than aspirin alone in reducing asymptomatic 
embolization in patients with recently symptomatic 
carotid stenosis45. 
A systematic review identifi ed four randomized 
trials directly comparing oral anticoagulants (OAC) 
high International Normalized Ratio (INR) (3.0-4.5) 
versus antiplatelet therapy in patients with previous 
TIA or minor stroke of presumed arterial origin67. 
Th erapy with OAC was associated with a signifi cantly 
higher rate of recurrent serious vascular events (1.70, 
95%CI 1.12-2.59), with a highly signifi cant excess of 
major bleeding complication (9.02, 95%CI 3.91-20.84) 
and a signifi cant excess of recurrent serious vascular 
events or major hemorrhage (2.30, 95%CI 1.58-3.53) 
compared with antiplatelet therapy. Th erapy with 
OAC was associated with a signifi cant excess of death 
from any cause compared with antiplatelet therapy 
(RR 2.38, 95%CI 1.31-4.32).
Recommendation for Best Medical Treatment in
Patients with Carotid Atherosclerosis
Th e best medical treatment of patients with carotid 
stenosis includes treatment of hypertension, diabetes 
mellitus, lipid or homocysteine metabolic disorders, 
modifi cation of lifestyle, and statin and antithrom-
botic treatment (Class I, level A).
Patients presenting with ischemic symptoms not 
taking antiplatelet therapy should be considered for 
aspirin with a loading dose of 160-300 mg if they are 
at a low risk of recurrent event, clopidogrel if allergic 
or intolerant of aspirin, and clopidogrel or the combi-
nation of aspirin and dipyridamole if at a high risk of 
recurrent event. Th e two strategies being similar, the 
choice between combined aspirin plus dipyridamole, 
and clopidogrel is based on the presence of coexistent 
disorders, tolerability and cost. Alternatively, aspirin 
alone, dipyridamole alone, or trifl usal alone may be 
used (Class I, level A).
Patients presenting with ischemic symptoms al-
ready taking aspirin should be considered to stop as-
pirin and start clopidogrel, or adding dipyridamole to 
aspirin, but not adding clopidogrel to aspirin.
Patients presenting with ischemic symptoms al-
ready taking clopidogrel should be considered to stay 
on clopidogrel, or changing to aspirin or the combina-
tion of dipyridamole and aspirin, but not adding aspi-
rin to clopidogrel.
Patients presenting with ischemic symptoms al-
ready taking the combination of aspirin and clopi-
dogrel should be considered for further therapy ac-
cording to the risk of a recurrent ischemic event with 
all vascular risk factors well controlled. Patients at a 
low risk of recurrent event should be considered for 
aspirin monotherapy. Patients at a higher risk should 
be considered for clopidogrel monotherapy or the 
combination of dipyridamole and aspirin. Patients 
having received stent placement should continue dual 
therapy with aspirin and clopidogrel for 8 weeks, then 
continue therapy with aspirin alone.
It is recommended that anticoagulation should 
not be used after non-cardioembolic ischemic stroke 
(Class I, Level A). High-intensity anticoagulation 
(INR 3.0-4.5) is more hazardous than eff ective in 
comparison with antiplatelet therapy.
Carotid Endarterectomy 
Carotid endarterectomy is a surgical procedure of 
plaque removal from the carotid artery, reducing the 
risk of stroke by enlarging the lumen and by remov-
ing the possible source of emboli. Th e ECSCT and 
NASCET1,2 results established CEA as the treat-
ment of choice for moderate and severe carotid artery 
stenosis in secondary stroke prevention. Th e most im-
portant risks of CEA are death (about 1%) and stroke 
(about 5%)1,2. From a pooled analysis of data from the 
three largest RCTs of surgery for symptomatic carotid 
stenosis68, CEA reduced 5-year absolute risk of any 
stroke or death in patients with 50%-69% stenosis, ac-
cording to angiographic NASCET criteria (absolute 
risk reduction (ARR) 7.8%, 95%CI 3.1-12.5), and was 
highly benefi cial in patients with 70%-99% stenosis 
(15.3%, 95%CI 9.8-20.7), but showed no benefi t in 
patients with near occlusion. Quantitatively similar 
results were seen for disabling stroke68. CEA there-
fore proved to be benefi cial in stenosis more than 50% 
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according to NASCET criteria, which is equivalent to 
65% stenosis by ECST criteria. In ECST trial, CEA 
reduced the risk of recurrent TIA in patients with 
near occlusion (ARR 15%; P=0.007). 
Th e degree of stenosis is a major determinant 
of benefi t from CEA, but there are other clinical 
characteristics that infl uence the risks and benefi ts 
of surgery. Subgroup analyses of pooled data from 
the large RCT69 showed the greatest benefi t from 
CEA in men, patients aged >75 years, and patients 
randomized within 2 weeks after their last ischemic 
event. Both ECST and NASCET showed that for 
patients with >50% ICA stenosis, the number need-
ed to treat (NNT) by CEA to prevent one ipsilateral 
stroke in 5 years was 9 for men versus 36 for women, 
5 for age >75 years versus 18 for age <65 years, and 5 
for patients randomized within 2 weeks after the last 
ischemic event versus 125 for patients randomized 
in >12 weeks. Women had a lower risk of ipsilateral 
ischemic stroke on medical treatment and a higher 
operative risk in comparison to men70. CEA was 
more benefi cial in women with >70% stenosis, but 
not in women with 50%-69% stenosis. At the same 
time, CEA reduced the 5-year ARR by 8.0% (3.4-
12.5) in men with 50%-69% stenosis. Sex diff erence 
was statistically signifi cant even when the analysis of 
the interaction was confi ned to the group with 50%-
69% stenosis70.
Trials of carotid surgery for asymptomatic carotid 
stenosis have concluded that, although surgery reduc-
es the incidence of ipsilateral stroke (RR 0.47-0.54) 
and any stroke, the absolute benefi t is small (approxi-
mately 1% per year)49,50,52, whereas the perioperative 
stroke or death rate is 3%. Medical management is 
the most appropriate option for most asymptomatic 
subjects; only centers with a perioperative complica-
tion rate of 3% or less should contemplate surgery. 
Patients with a high risk of stroke (men with stenosis 
of more than 80% and a life expectancy of more than 
5 years) may derive some benefi t from surgery in ap-
propriate centers50,52. 
Th ere are diff erent techniques of CEA. In tra-
ditional endarterectomy, the plaque is removed via 
a longitudinal arteriotomy. Eversion endarterectomy 
is a variant, which employs a transverse arteriotomy 
and re-implantation of the carotid artery. Th ere was 
no signifi cant diff erence in the rates of periopera-
tive stroke, stroke or death and local complication 
rates in a review of fi ve RCTs comparing eversion 
and conventional endarterectomy performed either 
with primary closure or patch angioplasty71. Th e 
absolute risks were rather low (the risk of stroke or 
death 1.7% with eversion versus 2.6% with conven-
tional endarterectomy). To reduce the risk of rest-
enosis, many surgeons use a patch of autologous vein 
or synthetic material to close the artery and enlarge 
the lumen. Although patch increases the operative 
time and complication rate, it was associated with 
60% reduction in the operative risk of stroke or death 
during the postoperative period and long-term fol-
low up, 85% reduction in the risk of perioperative 
arterial occlusion and 80% reduction in the risk of 
restenosis during long-term follow up72. Although 
some surgeons routinely insert a temporary intralu-
minal shunt during CEA, it is associated with some 
risk of dissection or transmission of emboli. RCTs 
that included patients requiring shunting or followed 
diff erent shunting policies were too small and the re-
sults were inconclusive73. 
CEA was traditionally performed under general 
anesthesia (GA), but surgery under local anesthe-
sia (LA) is becoming more widespread. With LA, a 
lower shunt rate is present due to immediate obvious 
need for it to restore blood fl ow distal to the carotid 
clamps. While a systematic review of seven small ran-
domized trials showed that the use of LA was asso-
ciated with a borderline statistically signifi cant trend 
towards a reduced risk of operative death, but no evi-
dence of reduction in the risk of operative stroke74, a 
large multicenter randomized trial (GALA) showed 
no major diff erence in the operative risk of stroke and 
death combined (risk ratio for LA vs. GA 0.94; 95% 
CI 0.70-1.27)75.
Recommendation for Carotid Endarterectomy 
CEA is recommended for patients with 70%-99% 
stenosis (Class I, Level A). CEA should only be per-
formed in centers with a perioperative complication 
rate (all strokes and death) of less than 6% (Class I, 
Level A). 
It is recommended that CEA be performed as soon 
as possible after the last ischemic event, ideally within 
2 weeks (Class II, Level B). 
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It is recommended that CEA may be indicated for 
certain patients with stenosis of 50%-69%; males with 
very recent hemispheric symptoms are most likely to 
benefi t (Class III, Level C). CEA for stenosis of 50%-
69% should only be performed in centers with a pe-
rioperative complication rate (all stroke and death) of 
less than 3% (Class I, Level A). 
CEA is not recommended for patients with steno-
sis of less than 50% (Class I, Level A).
Th ere is no evidence for the routine use of shunts 
during CEA (Class I, Level A).
Carotid patch angioplasty reduces the risk of oc-
clusion and restenosis, as well as the risk of combined 
stroke/death (Class I, Level A), but diff erences be-
tween the outcomes with diff erent patch materials 
are small to draw fi rm conclusions and recommenda-
tions.
Th e choice of the CEA technique should depend 
on the experience and familiarity of the individual 
surgeon (Class I, Level C).
Both LA and GA are safe. Th e anesthetist and 
surgeon, in consultation with the patient, should de-
termine the method of anesthesia. For patients with a 
contralateral carotid occlusion, LA might off er some 
benefi t (Class I, Level C).
It is recommended that patients remain on anti-
platelet therapy both before and after surgery (Class 
I, Level A) 
Carotid surgery is not recommended for asymp-
tomatic individuals with signifi cant carotid stenosis 
(NASCET 60%-99%), except for those at a high risk 
of stroke (Class I, Level C), and then in centers with a 
perioperative complication rate (all strokes and death) 
of less than 3%.
Patients should be followed-up by both the refer-
ring physician and the surgeon (Class IV, level C).
Extracranial-Intracranial Anastomosis 
(EC-IC Bypass)
About 5%-10% of patients with carotid TIA or 
minor stroke have occlusion of the ICA origin, or oc-
casionally of distal ICA or proximal middle cerebral 
artery. Th ese lesions can be bypassed by anastomo-
sing a branch of the external carotid artery, usually 
the superfi cial temporal artery, via a skull bur hole to 
a cortical branch of the middle cerebral artery. Such 
collateral was developed to improve blood supply in 
the distal middle cerebral artery bed and to reduce the 
risk of stroke or the severity of stroke. However, in a 
RCT these anastomoses between the superfi cial tem-
poral and middle cerebral arteries were not benefi cial 
in preventing stroke in patients with middle cerebral 
artery or ICA stenosis or occlusion76.
Carotid Stenting
Several trials compared CAS and CEA in second-
ary stroke prevention51,77-82,86. None of these studies 
was adequately powered to show the non-inferiority 
(or superiority) of stenting compared to endarterec-
tomy with regard to an endpoint combining the early 
risks and late benefi ts of the procedures. Most studies 
were designed to assess the non-inferiority of stenting 
compared to endarterectomy with regard to the early 
risks of the procedures. However, the SAPPHIRE 
trial included more than 70% of asymptomatic patients 
and therefore should not be used for decisions about 
secondary prevention51. In CAVATAS (Carotid and 
Vertebral Artery Transluminal Angioplasty Study), 
the majority of patients in the endovascular group 
underwent angioplasty and only 26% were treated 
with a stent86. Th e studies revealed diff erent results. 
SPACE (Stent-Protected Angioplasty versus Carotid 
Endarterectomy in symptomatic patients) marginally 
failed to prove the non-inferiority of CAS compared 
to CEA; for the endpoint ipsilateral stroke or death 
up to day 30, the event rates after 1,200 patients were 
6.8% for CAS and 6.3% for CEA patients (absolute 
diff erence 0.5%; 95% CI -1.9% to +2.9%; P=0.09)84. 
Th e French EVA3S (Endarterectomy versus Stenting 
in Patients with Symptomatic Severe Carotid Steno-
sis) trial was stopped prematurely after the inclusion 
of 527 patients because of safety concerns and lack 
of effi  cacy. Th e RR of any stroke or death after CAS 
compared with CEA was 2.5 (95% CI 1.2-5.1)77. 
CAS has not been shown to be as safe as CEA 
in patients with symptomatic carotid artery steno-
sis in RCTs. Recent meta-analyses83-85 of RCTs that 
compared CAS and CEA treatment of patients with 
mainly symptomatic carotid artery stenosis concluded 
that CEA should remain the fi rst line intervention in 
‘standard’ risk, symptomatic patients. 
In RCTs, the risk of ipsilateral stroke beyond the 
perioperative period was low (<1% per year) and simi-
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lar in both the stenting and endarterectomy groups, 
which strongly suggests that stenting is as eff ective 
as surgery for the medium-term prevention of ip-
silateral stroke, at least for the fi rst 4 years after the 
procedures79,80,82,86,89. As the incidence of recurrent ca-
rotid stenosis may be signifi cantly higher after CAS 
than after CEA87, there is a need to assess the long-
term eff ects of carotid stenting, and particularly the 
eff ect of restenosis. 
Th e SAPPHIRE trial selected high-risk patients 
with medical comorbidities that were exclusion cri-
teria for the NASCET/ACAS trial, with one of the 
following features: congestive heart failure (New York 
Heart Association class III/IV) and/or known severe 
left ventricular dysfunction; open heart surgery needed 
within 6 weeks; recent myocardial infarction (MI); un-
stable angina (Canadian Cardiovascular Society class 
III/IV); or severe pulmonary disease. In SAPPHIRE 
trial, the major adverse events (death, stroke and MI) 
at 1 year were 12.2% in the CAS group compared to 
20.1% in surgically treated patients (P=0.053). Still, it 
is unknown what the major adverse event rate would 
have been if patients had received the best medical 
treatment alone without any intervention. Th erefore, 
there is no indication from the literature that a high 
risk for CEA is also a high risk of stroke if medically 
treated, and a peri-interventional stroke or death risk 
of >3% in high risk for surgery patients with asymp-
tomatic carotid stenosis cannot be accepted. 
Subgroup analyses from RCTs suggest some het-
erogeneity of risk between stenting and endarterecto-
my. In particular, the excess risk associated with stent-
ing was greater in patients aged 70 years or older79,81,82. 
However, owing to the drawbacks of post hoc analyses 
such as low statistical power and the risk of chance 
fi ndings, these subgroup analyses should be inter-
preted with caution. Th e best evidence for subgroup 
treatment eff ect interaction will be obtained from a 
planned combined analysis of individual patient data 
from current trials that compare stenting with endar-
terectomy.
Recently, fi nal results of ICSS trial were presented 
at the European Stroke Conference 200988. Th e ICSS 
trial was a randomized double-blind study comparing 
CAS and CEA in patients with symptomatic carotid 
stenosis of greater than 50% within 6 months prior to 
randomization. A total of 1710 patients were included 
in the intention-to-treat (ITT) analysis, 853 random-
ized to CAS and 857 to CEA. Th e primary aim of the 
ICSS trial was to determine long-term survival free 
from disabling stroke. Suffi  cient follow up for this end 
point is expected to be completed in 2011 but the pri-
mary safety data on the 30-day rate of stroke, MI, or 
death, measured up to 120 days after randomization 
were presented. Th ose allocated to CAS had more 
events than those allocated to CEA (ITT analysis 
8.5% vs. 5.1, per protocol 7.4% vs. 4.0%, ARR=3.4%; 
P=0.004). Th e majority of these events were strokes, 
with nearly twice as many strokes in the CAS group 
than in the CEA group (65 vs. 34). In the magnetic 
resonance imaging (MRI) sub-study that was carried 
out at 5 ICSS centers, scans were analyzed blind to 
treatment. New ischemia was found in about half of 
CAS patients vs. about 15% of CEA patients. On fol-
low up imaging 4 to 6 weeks later, FLAIR was ab-
normal at the site of early ischemia in 30% of patients 
after CAS vs. 8% of patients after CEA, also highly 
signifi cant. 
Immediately afterwards, the Registry of CAS 
patients (recruited to post-marketing surveillance in 
the EXACT and CAPTURE ‘high risk for CEA’ 
Registries) reported 30-day outcomes87. Subgroup 
analysis stratifi ed for age was performed in a cohort 
of 6320 patients, 12% of them having suff ered stroke 
or TIA 6 months prior to CAS (equivalent to recent-
ly symptomatic in ICSS). Th e 30-day rate of death/
stroke in 589 patients aged <80 years was 5.3% (95% 
CI 3.6%-7.4%), compared to 10% in 172 patients aged 
>80 years (95%CI 3.3%-16%). Th e authors concluded 
that CAS demonstrated real-world outcomes consis-
tent with the established American Heart Association 
(AHA) guidelines in symptomatic patients. Th ere are 
some questions to be answered before implying these 
results on recommending CAS to patients at a high 
risk for CEA90. Th e low procedural risk observed in 
non-octogenarian patients in the amalgamated Reg-
istry must be maintained and regularly audited. If it 
exceeds 8%, it is unlikely that any long-term benefi t 
will accrue to the patients and the interventionist 
should review his/her selection criteria. Also, a re-
quest to the interventionists is to recognize that the 
magnitude of the benefi t conferred to the patient in 
terms of secondary stroke prevention will be increased 
if their interventions are primarily undertaken in pa-
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tients who also present with criteria of ‘high risk for 
stroke’, that means male sex, hemispheric ischemic 
symptoms, increasing medical comorbidity, very re-
cent symptoms, more severe degrees of stenosis, and 
contralateral occlusion91. A very important issue on 
assessing the risk for CAS is whether the patient had 
primary atherosclerotic disease or non-atherosclerotic 
disease (e.g., radiation arteritis, restenosis after CEA, 
etc.). In many of the ‘high risk’ registries published to 
date, up to 40% of patients had restenosis after CEA. 
Although this is likely to be more of a confounding 
factor in asymptomatic patients, secondary analyses 
from the Acculink for Revascularization of Carot-
ids in High Risk Patients (ARCHeR) CAS Registry 
showed that the 30-day risk following CAS in pa-
tients with non-atherosclerotic disease was 14 times 
lower in these patients (overall risk=6.6%, but 0.7% in 
non-atherosclerotic patients vs. 9.5% in patients with 
atherosclerosis)92.
Still, the biggest question is why the reduction in 
the procedural risk after CAS in non-randomized, 
observational studies is lower than in RCT. In 2001, 
CAVATAS was heavily criticized for the high proce-
dural risk after both CEA and CAS. However, while 
the 30-day risk after CEA improved from 9.9% ob-
served in CAVATAS (SPACE 6.3%, EVA-3S 3.9%, 
and ICSS 5.1%), the same does not apply to CAS 
(CAVATAS 10.0%, SPACE 6.8%, EVA-3S 9.6%, and 
ICSS 8.5%). Numerous factors are likely to be respon-
sible for the excess risk of procedural stroke observed 
in RCT. Th ere is a number of methodological criti-
cisms regarding CAS practice in each of these trials; 
the biggest one is the interventionist experience, but 
also the use of protection devices. Also, other factors 
should be taken in consideration such as stent types, 
protection type devices, sex, age, presenting symp-
toms, symptoms to intervention, medical comorbid-
ity, and patient selection criteria in order to identify 
cohorts of recently symptomatic patients that are 
predicted to be at either high or low risk of suff ering 
procedural stroke after CAS. A very important ques-
tion is whether rapid intervention infl uences the early 
procedural risk, but also enables the biggest benefi t of 
intervention. Th e risk of stroke after a TIA or minor 
stroke is highest in the fi rst seven days of symptom 
onset. Th ere is compelling evidence that any delay in 
intervention rapidly diminishes the benefi t accruing 
to the patient93. Accordingly, the CAS Registries and 
any future meta-analyses of the RCT must go back 
and evaluate the relationship between the time from 
symptom onset to treatment and then specifi cally re-
late it to the procedural risk. It is no longer accept-
able to simply provide outcome risk data for patients 
treated within 6 months of symptoms. Consecutively, 
better information on outcomes of the preferred in-
tervention (CEA or CAS) in patients treated within 7 
or 14 days of symptom onset would be available. Th is 
could mean that one intervention might be safer in the 
hyperacute phase of treatment, while the other might 
be preferable after some time has elapsed. Especially, 
results of the CAPTURE CAS Registry94 have point-
ed to this, showing by subgroup analysis that the 30-
day risk of death/stroke was 2.5 times higher if CAS 
was performed within two weeks of the most recent 
symptom (P<0.05), whereas there was no diff erence in 
the procedural risk after four weeks. 
Certain vascular and local anatomic features are 
considered as relative contraindications depending on 
the experience of interventional radiologist and type of 
procedural material for CAS, e.g., complex bifurcation 
disease with long, multifocal lesions or extensive aor-
tic or brachiocephalic trunk plaque, severe tortuosity 
or calcifi cation of the aortic arch vessel, or ring-like, 
heavy calcifi cations of the carotid bifurcation. Con-
trary, based on experts’ opinion and not on RCTs95, 
CAS is indicated in patients with contralateral laryn-
geal nerve palsy and previous radical neck dissection 
or cervical irradiation and with prior CEA (restenosis), 
because the rate of cranial nerve injuries following sur-
gery is higher in this subset. Also, CAS can be off ered 
to patients with high bifurcation or intracranial exten-
sion of a carotid lesion, where surgical access could be 
diffi  cult, or in patients at a high risk of cerebral isch-
emia during carotid clamping (occlusion of the con-
tralateral ICA and anomalies of the Willis circle).  
While pending CREST publication, carotid stent-
ing in symptomatic patent with standard risk should 
be off ered in high volume CAS centers that already 
treat ‘standard risk’ symptomatic patients only if the 
30-day risk of death/stroke is independently audited 
and maintained at <6% and patients are treated with-
out delay, preferably within 14 days. If these two cave-
ats cannot be achieved, the patient should be referred 
for CEA.
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Recommendation for Carotid Stent Placement
Until the results of the ongoing trials are available 
for a pooled analysis of safety and long-term eff ec-
tiveness, stenting should not be routinely off ered to 
patients suitable for carotid endarterectomy. 
Carotid percutaneous transluminal angioplasty 
and stenting (CAS) is recommended in selected pa-
tients (Class I, Level A). It should be restricted to the 
following subgroups of patients with severe symp-
tomatic carotid artery stenosis: those with contrain-
dications for CEA, stenosis at a surgically inaccessible 
site, restenosis after earlier CEA, and post-radiation 
stenosis (Class IV, GCP). 
Th e procedure should be restricted to high volume 
CAS centers, with interventional radiologists experi-
enced in diff erent stent types and protection devices, 
and with the known perioperative complication rate 
of <6%. 
Patients should receive a combination of clopi-
dogrel and aspirin immediately before and for at least 
1 month after stenting (Class IV, GCP). 
Carotid angioplasty, with or without stenting, is 
not recommended for patients with asymptomatic ca-
rotid stenosis (Class IV, GCP). 
Stenting of Intracranial Artery Stenosis 
Patients with symptomatic intracranial stenosis 
of ≥50% are at a high risk of recurrent strokes, both 
in the anterior and posterior circulation (12% after 
1 year and 15% after 2 years in the territory of the 
stenosed artery)96,97. Severe stenosis (≥70%) carries a 
higher risk than moderate stenosis (50% to <70%)97. 
Since no RCTs were designed to evaluate angioplasty, 
stenting or both for intracranial stenosis, data derive 
from several non-randomized trials that showed fea-
sibility and acceptable safety of intracranial stenting 
with the high risk of restenosis98,99. Th e incidence of 
complications after either angioplasty or stenting may 
be up to 6%98.
Recommendations for Stenting of Intracranial Artery 
Stenosis
For patients with hemodynamically signifi cant 
intracranial stenosis that have symptoms despite 
medical therapies (antithrombotics, statins, and other 
treatments for risk factors), the usefulness of endovas-
cular therapy (angioplasty and/or stent placement) is 
uncertain and is considered investigational (Clas II, 
Level C). 
References
  1. North American Symptomatic Carotid Endarterectomy Trial 
Collaborators. Benefi cial eff ect of carotid endarterectomy in 
symptomatic patients with high-grade carotid stenosis. N 
Engl J Med 1991;325:445-53.
  2. European Carotid Surgery Trialists’ Collaborative Group. 
MRC European Carotid Surgery Trial: interim results for 
symptomatic patients with severe (70-99%) or with mild 
(0-20%) carotid stenosis. Lancet 1991;337:1235-43.
  3. SANDERCOCK PA, WARLOW CP, JONES LN, STAR
KEY IR. Predisposing factors for cerebral infarction: the Ox-
fordshire Community Stroke Project. BMJ 1989;298:75-80. 
  4. DEMARIN V, LOVRENČIĆHUZJAN A, eds. Neuro-
sonologija. Zagreb: Školska knjiga, 2009.
  5. HANKEY GJ. Stroke treatment and prevention: an evidence-
based approach. New York: Cambridge University Press, 
2005.
  6. MORGENSTERN LB, FOX AJ, SHARPE BL, ELISZIW 
M, BARNETT HJ, GROTTA JC. Th e risks and benefi ts of 
carotid endarterectomy in patients with near occlusion of the 
carotid artery. Neurology 1997;48:911-5.
  7. ROTHWELL PM, WARLOW CP. Low risk of ischaemic 
stroke in patients with collapse of the internal carotid artery 
lumen diameter distal to severe symptomatic carotid steno-
sis: cerebral protection due to low post-stenotic fl ow? Stroke 
2000;31:622-30.
  8. LOVETT J, DENNIS M, SANDERCOCK PAG, BAM
FORD J, WARLOW CP, ROTHWELL PM. Th e very 
early risk of stroke following a TIA. Stroke 2003;34:138-40.
  9. COULL AJ, LOVETT JK, ROTHWELL PM. Population 
based study of early risk of stroke after transient ischemic at-
tack or minor stroke: implications for public education and 
organisation of services. BMJ 2004;328:326-8.
10. BRAININ M, BARNES M, BARON JC, GILHUS NE, 
HUGHES R, SELMAJ K, et al. Guidance for the prepara-
tion of neurological management guidelines by EFNS scien-
tifi c task forces – revised recommendations 2004. Eur J Neu-
rol 2004;11:577-81.
11. EASTON JD, SAVER JL, ALBERS GW, ALBERTS MJ, 
CHATURVEDI S, FELDMANN E, et al. Defi nition and 
evaluation of transient ischemic attack. Stroke 2009;40:2276-
93.
12. DENNIS M, BAMFORD J, SANDERCOCK P, WAR
LOW C. Prognosis of transient ischemic attacks in the Ox-
fordshire Community Stroke Project. Stroke 1990;21:848-53.
13. BOGOUSSLAVSKY J, Van MELLE G, REGLI F. Th e 
Lausanne Stroke Registry: analysis of 1,000 consecutive pa-
tients with fi rst stroke. Stroke 1988;19:1083-92.
Book Acta 1-2010.indb   114 14.6.2010   9:23:12
Acta Clin Croat,  Vol. 49,  No. 1,  2010 115
Vida Demarin et al. Recommendations for the management of patients with carotid stenosis
14. SACCO RL. Risk factors for TIA and TIA as a risk factor 
for stroke. Neurology 2004;62:S7-11.
15. MOHR JP, CAPLAN LR, MELSKI JW, GOLDSTEIN 
RJ, DUNCAN GW, KISTLER JP, et al. Th e Harvard Co-
operative Stroke Registry. A prospective registry. Neurology 
1978;28:754-62.
16. SACCO RL, ELLENBERG JH, MOHR JP, TATEM
ICHI TK, HIER DB, PRICE TR, et al. Infarcts of undeter-
mined cause: the NINCDS Stroke Data Bank. Ann Neurol 
1989;25:382-90.
17. ROTHWELL PM, WARLOW CP. Timing of TIAs pre-
ceding stroke: time window for prevention is very short. Neu-
rology 2005;64:817-20.
18. FARRELL B, GODWIN J, RICHARDS S, WARLOW 
C. Th e United Kingdom Transient Ischaemic Attack (UK-
TIA) aspirin trial: fi nal results. J Neurol Neurosurg Psychia-
try 1991;54:1004-54.
19. European Carotid Surgery Trialists’ Collaborative Group. 
Randomised trial of endarterectomy for recently symptomatic 
carotid stenosis: fi nal results of the MRC European Carotid 
Surgery Trial (ECST). Lancet 1998;351:1379-87.
20. LISABETH LD, IRELAND JK, RISSER JM, BROWN 
DL, SMITH MA, GARCIA NM, et al. Stroke risk af-
ter transient ischemic attack in a population-based setting. 
Stroke 2004;35:1842-6.
21. FRIEDMAN GD, WILSON WS, MOSIER JM, COL
ANDREA MA, NICHAMAN MZ. Transient ischemic 
attacks in a community. JAMA 1969;210:1428-34.
22. CALANDRE L, BEMEJO F, BALSEIRO J. Long-term 
outcome of TIAs, RINDs and infarctions with minimum 
residuum: a prospective study in Madrid. Acta Neurol Scand 
1990;82:104-8.
23. HANKEY GJ, SLATTERY JM, WARLOW CP. Th e prog-
nosis of hospital-referred transient ischaemic attacks. J Neu-
rol Neurosurg Psychiatry 1991;54:793-802.
24. HANKEY GJ, SLATTERY JM, WARLOW CP. Transient 
ischaemic attacks: which patients are at high (and low) risk 
of serious vascular events? J Neurol Neurosurg Psychiatry 
1992;55:640-52.
25. KLEINDORFER D, PANAGOS P, PANCIOLI A, 
KHOURY J, KISSELA B, WOO D, et al. Incidence and 
short-term prognosis of transient ischemic attack in a popula-
tion-based study. Stroke 2005;36:720-3.
26. JOHNSTON SC, GRESS DR, BROWNER WS, SIDNEY 
S. Short-term prognosis after emergency department diagno-
sis of transient ischemic attack. JAMA 2000;284:2901-6.
27. ELIASZIW M, KENNEDY J, HILL MD, BUCHAN 
AM, BARNETT HJ. Early risk of stroke after a transient 
ischemic attack in patients with internal carotid artery dis-
ease. CMAJ 2004;170:1105-9.
28. DAFFERTSHOFER M, MIELKE O, PULLWITT A, 
FELSENSTEIN M, HENNERICI M. Transient ischemic 
attacks are more than “ministrokes”. Stroke 2004;35:2453-8.
29. JOHNSTON SC, ROTHWELL PM, NGUYENHUYNH 
MN, GILES MF, ELKINS JS, BERNSTEIN AL, et al. 
Validation and refi nement of score to predict very early stroke 
risk after transient ischaemic attack. Lancet 2007;369:283-
92.
30. PURROY F, MONTANER J, ROVIRA A, DELGADO P, 
QUINTANA M, ALVAREZSABIN J. Higher risk of fur-
ther vascular events among transient ischemic attack patients 
with diff usion-weighted imaging acute ischemic lesions. 
Stroke 2004;35:2313-9.
31. DEMARIN V, LOVRENČIĆHUZJAN A, TRKANJEC 
Z, VUKOVIĆ V, VARGEKSOLTER V, ŠERIĆ V, et al. 
Recommendations for stroke management – 2006 update. 
Acta Clin Croat 2006;45:219-85.
32. LOVRENČIĆHUZJAN A, VUKOVIĆ V, DEMARIN V. 
Neurosonology in stroke. Acta Clin Croat 2006;45:385-401. 
33. HACKE W, KASTE M, BOGOUSSLAVSKY J, BRAI
NIN M, CHAMORRO A, LEES K, et al. Acute stroke. 
In: HUGHES R, BRAININ M, GILHUS NE, eds. Euro-
pean handbook of neurological management. Massachusetts: 
Blackwell Publishing, 2006:123-58.
34. GOLDSTEIN LB, ADAMS R, ALBERTS MJ, APPEL 
LJ, BRASS LM, BUSHNELL CD, et al.; American Heart 
Association; American Stroke Association Stroke Council. 
Primary prevention of ischemic stroke: a guideline from the 
American Heart Association/American Stroke Association 
Stroke Council: cosponsored by the Atherosclerotic Periph-
eral Vascular Disease Interdisciplinary Working Group; Car-
diovascular Nursing Council; Clinical Cardiology Council; 
Nutrition, Physical Activity, and Metabolism Council; and 
the Quality of Care and Outcomes Research Interdisciplinary 
Working Group. Circulation 2006;113:873-923. 
35. RUNDEK T. Ultrasonographic atherosclerotic plaque mor-
phology and TCD monitoring of asymptomatic emboliza-
tion. In: MOUSA I, RUNDEK T, MOHR JP, eds. Risk 
stratifi cation and management of patients with asymptomatic 
carotid artery disease. New York: Taylor and Francis Group 
of London, 2006: fale stranice poglavlja od-do.
36. LAVALLEE PC, MESEGUER E, ABBOUD H, CABRE
JO L, OLIVOT JM, SIMON O, et al. A transient ischaemic 
attack clinic with round-the-clock access (SOS-TIA): feasi-
bility and eff ects. Lancet Neurol 2007;6:953-60.
37. ROTHWELL PM, GILES MF, CHANDRATHEVA A, 
MARQUARDT L, GERAGHTY O, REDGRAVE JN, et 
al. Eff ect of urgent treatment of transient ischaemic attack and 
minor stroke on early recurrent stroke (EXPRESS study): a 
prospective population-based sequential comparison. Lancet 
2007;370:1432-42.
38. CALVET D, LAMY C,TOUZE E, OPPENHEIM C, 
MEDER JF, MAS JL. Management and outcome of patients 
with transient ischemic attack admitted to a stroke unit. 
Cerebrovasc Dis 2007;24:80-5.
39. CARROLL BA. Duplex sonography in patients with hemi-
spheric symptoms. J Ultrasound Med 1989;8:535-40.
Book Acta 1-2010.indb   115 14.6.2010   9:23:12
Vlasta Vuković et al. Gabapentin in the prophylaxis of cluster headache: an observational open label study
116 Acta Clin Croat,  Vol. 49,  No. 1,  2010
40. WIDJAJA E, MANUEL D, HODGSON TJ, CONNOL
LY DJ, COLEY SC, ROMANOWSKI CA, et al.; Shef-
fi eld Stroke Prevention Group. Imaging fi ndings and refer-
ral outcomes of rapid assessment stroke clinics. Clin Radiol 
2005;60:1076-82.
41. LOVRENČIĆHUZJAN A, BOSNARPURETIĆ M, 
VUKOVIĆ V, MALIĆ M, THALLER N, DEMARIN V. 
Correlation of carotid color Doppler and angiographic fi nd-
ings in patients with symptomatic carotid artery stenosis. 
Acta Clin Croat 2000;39:215-20.
42. BUSKENS E, NEDERKOORN PJ, BUIJS-Van Der 
WOUDE T, MALI WP, KAPPELLE LJ, EIKELBOOM 
BC, et al. Imaging of carotid arteries in symptomatic pa-
tients: cost-eff ectiveness of diagnostic strategies. Radiology 
2004;233:101-12.
43. PURROY F, MONTANER J, DELGADO P, ARENIL
LAS JF, MOLINA CA, SANTAMARINA E, et al. Use-
fulness of urgent combined carotid/transcranial ultrasound 
testing in early prognosis of TIA patients. Med Clin (Barc) 
2006;126:647-50. (in Spanish)
44. FELDMANN E, WILTERDINK JL, KOSINSKI A, 
LYNN M, CHIMOWITZ MI, SARAFIN J, et al. Th e 
Stroke Outcomes and Neuroimaging of Intracranial Athero-
sclerosis (SONIA) trial. Neurology 2007;68:2099-106.
45. MARKUS HS, DROSTE DW, KAPS M, LARRUE V, 
LEES KR, SIEBLER M, et al. Dual antiplatelet therapy with 
clopidogrel and aspirin in symptomatic carotid stenosis evalu-
ated using Doppler embolic signal detection: the Clopidogrel 
and Aspirin for Reduction of Emboli in Symptomatic Carotid 
Stenosis (CARESS) trial. Circulation 2005;111:2233-40.
46. POPPERT H, SADIKOVIC S, SANDER K, WOLF O, 
SANDER D. Embolic signals in unselected stroke patients: 
prevalence and diagnostic benefi t. Stroke 2006;37:2039-43.
47. BARNET HJ, ELIASZIW M, MELDRUM HE, TAY
LOR DW. Do the facts and fi gures warrant a 10-fold increase 
in the performance of carotid endarterectomy on asymptom-
atic patients? Neurology 1996;46:603-8.
48. QURESHI AI, ALEXANDROV AV, TEGELER CH, 
HOBSON RW, BAKER DJ, HOPKINS LN. Guidelines 
for screening of extracranial carotid artery disease: a state-
ment for healthcare professionals from the Multidisciplinary 
Practice Guidelines Committee of the American Society of 
Neuroimaging; cosponsored by the Society of Vascular and 
Interventional Neurology. J Neuroimaging 2007;17:19-47.
49. Executive Committee for the Asymptomatic Carotid Ath-
erosclerosis Study. Endarterectomy for asymptomatic carotid 
artery stenosis. JAMA 1995;273:1421-8.
50. HALLIDAY A, MANSFIELD A, MARRO J, PETO C, 
PETO R, POTTER J, et al.; MRC Asymptomatic Carotid 
Surgery Trial (ACST) Collaborative Group. Prevention of 
disabling and fatal strokes by successful carotid endarterec-
tomy in patients without recent neurological symptoms: ran-
domised controlled trial. Lancet 2004;363:1491-502.
51. YADAV JS, WHOLEY MK, KUNTZ RE, FAYAD P, 
KATZEN BT, MISHKEL GJ, et al. Protected carotid artery 
stenting versus endarterectomy in high-risk patients. N Engl J 
Med 2004;351:1493-501.
52. CHAMBERS BR, DONNAN GA. Carotid endarterec-
tomy for asymptomatic carotid stenosis. Cochrane Data Syst 
Rev 2005;4:CD001923.
53. European Stroke Organisation (ESO) Executive Commit-
tee; ESO Writing Committee Collaborators. Guidelines for 
management of ischaemic stroke and transient ischaemic at-
tack 2008. Cerebrovasc Dis 2008;25:457-507.
54. COSTA J, FERRO JM, MATIASGUIU J, ALVAEREZ
SABIN J, TORRES F. Trifl usal for preventing serious vascu-
lar events in people at high risk. Cochrane Database Syst Rev 
2005;3:CD004296 
55. O’DONNEL MJ, HANKEY GJ, EIKELBOOM JW. An-
tiplatelet therapy for secondary prevention of noncardioem-
bolic stroke: a critical review. Stroke 2008;39:1638-46.
56. CAMPBELL CL, SMYTH S, MONTALESCOT G, 
STEINHUBL SR. Aspirin dose for the prevention of cardio-
vascular disease: a systematic review. JAMA 2007;297:2018-24.
57. Antithrombotic Trialists’ Collaboration. Collaborative meta-
analysis of randomised trials of antiplatelet therapy for pre-
vention of death, myocardial infarction, and stroke in high 
risk patients. BMJ 2002;324:71-86.
58. HALKES PH, GRAY LJ, BATH PM, DIENER HC, 
GUIRAUDCHAUMEIL B, YATSU FM, et al. Dipyrida-
mole plus aspirin versus aspirin alone in secondary prevention 
after TIA or stroke: a meta-analysis by risk. J Neurol Neuro-
surg Psychiatry 2008;79:1218-23.
59. THIJS V, LEMMENS R, FIEUWS S. Network meta-
analysis: simultaneous meta-analysis of common antiplatelet 
regimens after transient ischaemic attack or stroke. Eur Heart 
J 2008;29:1086-92.
60. CHAN FK, CHING JY, HUNG LC, WONG VW, LE
UNG VK, KUNG NN, et al. Clopidogrel versus aspirin and 
esomeprazole to prevent recurrent ulcer bleeding. N Engl J 
Med 2005;352:238-44.
61. CAPRIE Steering Committee. A randomised, blinded, trial 
of clopidogrel versus aspirin in patients at risk of ischaemic 
events (CAPRIE). Lancet 1996;348:1329-39.
62. DIENER HC, CUNHA L, FORBES C, SIVENIUS J, 
SMETS P, LOWENTHAL A. Dipyridamole and acetyl-
salicylic acid in the secondary prevention of stroke. J Neurol 
Sci 1996;143:1-13.
63. Th e ESPRIT Study Group. Aspirin plus dipyridamole versus 
aspirin alone after cerebral ischaemia of arterial origin (ES-
PRIT): randomised controlled trial. Lancet 2006;367:1665-
73.
64. SACCO  RL, DIENER HC, YUSUF S, COTTON D, 
OUNPUU S, LAWTON WA, et al. Aspirin and extended-
release dipyridamole versus clopidogrel for recurrent stroke. 
N Engl J Med 2008;359:1238-51.
Book Acta 1-2010.indb   116 14.6.2010   9:23:12
Acta Clin Croat,  Vol. 49,  No. 1,  2010 117
Vida Demarin et al. Recommendations for the management of patients with carotid stenosis
65. DIENER HC, BOGOUSSLAVSKY J, BRASS LM, 
CIMMINIELLO C, CSIBA L, KASTE M, et al. Aspirin 
and clopidogrel compared with clopidogrel alone after recent 
ischaemic stroke or transient ischaemic attack in high-risk 
patients (MATCH): randomised, double-blind, placebo-
controlled trial. Lancet 2004;364:331-7.
66. BHATT DL, TOPOL EJ. Clopidogrel added to aspirin 
versus aspirin alone in secondary prevention and high-risk 
primary prevention: rationale and design of the Clopidogrel 
for High Atherothrombotic Risk and Ischemic Stabilization, 
Management, and Avoidance (CHARISMA) Trial. Am 
Heart J 2004;148:263-8.
67. ALGRA A, De SCHRYVER EL, van GIJN J, KAPPELLE 
LJ, KOUDSTAAL PJ. Oral anticoagulants versus antiplate-
let therapy for preventing further vascular events after tran-
sient ischaemic attack or minor stroke of presumed arterial 
origin. Stroke 2003;34:234-5.
68. ROTHWELL PM, ELIASZIW M, GUTNIKOV SA, 
FOX AJ, TAYLOR DW, MAYBERG MR, et al. Analy-
sis of pooled data from the randomised controlled trials of 
endarterectomy for symptomatic carotid stenosis. Lancet 
2003;361:107-16.
69. ROTHWELL PM, ELIASZIW M, GUTNIKOV SA, 
WARLOW CP, BARNETT HJ. Endarterectomy for symp-
tomatic carotid stenosis in relation to clinical subgroups and 
timing of surgery. Lancet 2004;363:915-24.
70. ROTHWELL PM, GIBSON R, WARLOW CP. Th e in-
terrelation between plaque surface morphology and degree 
of stenosis on carotid angiograms and the risk of ischaemic 
stroke in patients with symptomatic carotid stenosis. Stroke 
2000;31:615-21.
71. CAO PF, SW EANGO P, ZANNETTI S, et al. Eversion 
versus conventional carotid endarterectomy for preventing 
stroke. Cochrane Database Syst Rev. 2000;4:CD001921.
72. BOND R, RERKASEM K, AbuRAHMA AF, NAYLOR 
AR, ROTHWELL PM. Patch angioplasty versus primary 
closure for carotid endarterectomy. Cochrane Database Syst 
Rev. 2004,2: CD000160.
73. BOND R, RERKASEM K, COUNSELL C, SALINAS R, 
NAYLOR R, WARLOW CP, et al. Routine or selective ca-
rotid artery shunting for carotid endarterectomy (and diff er-
ent methods of monitoring in selective shunting). Cochrane 
Database Syst Rev. 2002;2:CD000190.
74. RERKASEM K, BOND R, ROTHWELL PM. Local ver-
sus general anaesthesia for carotid endarterectomy. Cochrane 
Database Syst Rev. 2004;2:CD000126.
75. GALA Trial Collaborative Group. General anaesthesia versus 
local anaesthesia for carotid surgery (GALA): a multicentre, 
randomised controlled trial. Lancet 2008;372:2132-42.
76. Th e EC/IC Bypass Study Group. Failure of extracranial-
intracranial arterial bypass to reduce the risk of ischaemic 
stroke. Results of an international randomised trial. N Engl J 
Med 1985;313:1191-200.
77. MAS JL, CHATELLIER G, BEYSSEN B, BRANCHERE
AU A, MOULIN T, BECQUEMIN JP, et al. Endarterec-
tomy versus stenting in patients with symptomatic severe ca-
rotid stenosis. N Engl J Med 2006;355:1660-71.
78. RINGLEB PA, ALLENBERG J, BRUCKMANN H, 
ECKSTEIN HH, FRAEDRICH G, HARTMANN M, 
et al. 30-day results from the SPACE trial of stent-pro-
tected angioplasty versus carotid endarterectomy in symp-
tomatic patients: a randomised noninferiority trial. Lancet 
2006;368:1239-47.
79. MAS JL, TRINQUART L, LEYS D, ALBUCHER JF, 
ROUSSEAU H, VIGUIER A, et al. Endarterectomy Ver-
sus Angioplasty in Patients with Symptomatic Severe Carotid 
Stenosis (EVA-3S) trial: results up to 4 years from a ran-
domised, multicentre trial. Lancet Neurol 2008;7:885-92.
80. GURM HS, YADAV JS, FAYAD P, KATZEN BT, MISH
KEL GJ, BAJWA TK, et al. Long-term results of carotid 
stenting versus endarterectomy in high-risk patients. N Engl J 
Med 2008;358:1572-9. 
81. STINGELE R, BERGER J, ALFKE K, ECKSTEIN HH, 
FRAEDRICH G, ALLENBERG J, et al. Clinical and angio-
graphic risk factors for stroke and death within 30 days after 
carotid endarterectomy and stent-protected angioplasty: a sub-
analysis of the SPACE study. Lancet Neurol 2008;7:216-22. 
82. HOBSON RW, HOWARD VJ, ROUBIN GS, BROTT 
TG, FERGUSON RD, POMPA JJ, et al. Carotid artery 
stenting is associated with increased complications in octoge-
narians: 30-day stroke and death rates in the CREST lead-in 
phase. J Vasc Surg 2004;40:1106-11.
83. COWARD LJ, FEATHERSTONE RL, BROWN M 
M. Percutaneous transluminal angioplasty and stenting 
for carotid artery stenosis. Cochrane Database Syst Rev. 
2004;2:CD000515
84. RINGLEB PA, CHATELLIER G, HACKE W, FAVRE JP, 
BARTOLI JM, ECKSTEIN HH, et al. Safety of endovas-
cular treatment of carotid artery stenosis compared with sur-
gical treatment: a meta-analysis. J Vasc Surg 2008;47:350-5.
85. EDERLE J, FEATHERSTONE RL, BROWN MM. Ran-
domized controlled trials comparing endarterectomy and en-
dovascular treatment for carotid artery stenosis: a Cochrane 
systematic review. Stroke 2009;40:1373-80.
86. CAVATAS Investigators. Endovascular versus surgical treat-
ment in patients with carotid stenosis in the Carotid and Ver-
tebral Artery Transluminal Angioplasty Study (CAVATAS): 
a randomised trial. Lancet 2001;357:1729-37.
87. ECKSTEIN HH, RINGLEB P, ALLENBERG JR, 
BERGER J, FRAEDRICH G, HACKE W, et al. Results 
of the Stent-Protected Angioplasty versus Carotid Endart-
erectomy (SPACE) study to treat symptomatic stenoses at 2 
years: a multinational, prospective, randomised trial. Lancet 
2008;7:893-902.
88. BROWN MM, EDERLE J, BONATI LH, FEATHER
STONE RJ, DOBSON J. Safety results of the International 
Book Acta 1-2010.indb   117 14.6.2010   9:23:13
Vlasta Vuković et al. Gabapentin in the prophylaxis of cluster headache: an observational open label study
118 Acta Clin Croat,  Vol. 49,  No. 1,  2010
Carotid Safety Study (ICCS): early outcome of the patients 
randomised between carotid stenting and endarterectomy for 
symptomatic carotid stenosis. Cerebrovasc Dis 2009;27:10.
89. GRAY WA, CHATURVEDI S, VERTA P. Th irty-day out-
comes for carotid artery stenting in 6320 patients from two 
prospective, multicentre, high-surgical-risk registries. Circ 
Cardiovasc Intervent 2009;2:159-66.
90. NAYLOR AR. ICSS and EXACT/CAPTURE: More ques-
tions than answers. Eur J Vasc Endovasc Surg 2009;38:397-
401.
91. NAYLOR AR, ROTHWELL PM, BELL PRF. Overview 
of the principal results and secondary analyses from the Eu-
ropean and the North American randomised trials of carotid 
endarterectomy. Eur J Vasc Endovasc Surg 2003;26:115-29.
92. www.evtodayarchive.com/03_archive/0903/171.html 
93. MacDONALD S, LEE R, WILLIAMS R, STANSBY G. 
Towards safer carotid artery stenting: a scoring system for 
anatomic suitability. Stroke 2009;40:1698-703.
94. GRAY WA, YADAV JS, VERTA P, SCICLI A, FAIRMAN 
R, WHOLEY M, et al. Th e CAPTURE registry: predictors 
of outcomes in carotid artery stenting with embolic protec-
tion for high surgical risk patients in the early post-approval 
setting. Cathet Cardiovasc Intervent 2007;70:1025-33.
95. LIAPIS CD, SIR BELL PRF, MIKHAILIDIS D, SIVE
NIUS J, NICOLAIDES A, FERNANDES J, et al. ESVS 
Guidelines. Invasive treatment for carotid stenosis: indica-
tions, techniques. Eur J Vasc Endovasc Surg 2009;37:1-19.
96. CHIMOWITZ MI, LYNN MJ, HOWLETTSMITH 
H, STERN BJ, HERTZBERG VS, FRANKEL MR, et al. 
Comparison of warfarin and aspirin for symptomatic intrac-
ranial arterial stenosis. N Engl J Med 2005;352:1305-16.
97. KASNER SE, CHIMOWITZ MI, LYNN MJ, HOWL
ETTSMITH H, STERN BJ, HERTZBERG VS, et al. 
Predictors of ischemic stroke in the territory of a symptomatic 
intracranial arterial stenosis. Circulation 2006;113:555-63.
98. BOSE A, HARTMANN M, HENKES H, LIU HM, 
TENG MM, SZIKORA I, et al. A novel, self-expanding, ni-
tinol stent in medically refractory intracranial atherosclerotic 
stenoses: the Wingspan study. Stroke 2007;38:1531-7.
99. SSYLVIA Study investigators. Stenting of Symptomatic 
Atherosclerotic Lesions in the Vertebral or Intracranial Ar-
teries (SSYLVIA); study results. Stroke 2004;35:1388-92.
Sažetak
PREPORUKE ZA LIJEČENJE BOLESNIKA S KAROTIDNOM STENOZOM
U ovom članku objavljujemo preporuke za zbrinjavanje bolesnika sa stenozom karotidnih arterija, prihvaćene od Hr-
vatskoga društva za neurovaskularne poremećaje, Hrvatskoga neurološkog društva, Hrvatskoga društva za ultrazvuk u 
medicini i biologiji, Hrvatskoga radiološkog društva, Hrvatskoga društva za vaskularnu kirurgiju i Hrvatskoga društva 
za neurokirurgiju. Sastoje se od preporuka za neinvazivni probir bolesnika s karotidnom stenozom, preporuke za najbolje 
medikamentno liječenje te preporuka za intervenciju kao što je karotidna endarterektomija i postavljanje stenta, a zasno-
vane su na rezultatima internacionalnih randomiziranih kliničkih pokusa.
Ključne riječi: stenoza karotidne artrije, preporuke, karotidna endarterektomija, postavljanje stenta, duplex sonografi ja
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